Dihydromyricetin Bulk Powder is a flavonoid compound mainly found in the leaves of Ampelopsis pilosula (vine tea), and has received widespread attention in recent years due to its significant hepatoprotective effects. The following is a systematic introduction from three aspects: its mechanism of action, its protective effects against different liver diseases, and its safety.
Core Protection Mechanism
| Mechanism | Mode of Action | Key Pathways/Targets |
|---|---|---|
| Antioxidant | Scavenges reactive oxygen species (ROS), reduces oxidative stress | AMPK/Sirt-1/PGC-1α pathway |
| Anti-inflammatory | Inhibits release of inflammatory cytokines | FXR/NLRP3, TLR4/MyD88/NF-κB |
| Lipid metabolism regulation | Reduces fat synthesis, promotes fat breakdown | Lowers TG, TC, LDL-C |
| Repair promotion | Induces hepatocyte proliferation | Promotes liver tissue regeneration |
Abbreviations:
TG = Triglycerides
TC = Total Cholesterol
LDL-C = Low-Density Lipoprotein Cholesterol
Key Research Evidence
1. Alcoholic Liver Disease
In mouse studies of chronic alcoholic liver injury, Dihydromyricetin Bulk Powder treatment reduced transaminase levels by approximately 45-60%, decreased liver triglyceride levels by 50-70%, and significantly alleviated hepatocellular steatosis and inflammatory cell infiltration.
2. Metabolic Fatty Liver Disease
This is currently the area with the highest level of evidence. A randomized, double-blind, placebo-controlled trial published in 2025-2026 (55 patients with MASLD, 12-month intervention) found:
- The combined normalization rate of liver enzymes (ALT/GGT) was 35% in the DHM supplementation group, compared to only 5% in the placebo group (P=0.028).
- Glucose, total cholesterol, and LDL cholesterol all decreased significantly.
- Liver stiffness values were lower than baseline at both 6 and 12 months.
Researchers concluded that DHM supplementation for 6-12 months can improve liver enzymes, liver stiffness, and glucose and lipid metabolism parameters in MASLD patients.
3. Drug-induced liver injury
A 2025 mouse study showed that pretreatment with dihydromyricetin can reduce hepatotoxicity induced by the chemotherapy drug cyclophosphamide, manifested by decreased transaminase levels, increased antioxidant enzyme activity, and reduced liver pathological changes. Its protective mechanism is related to reducing oxidative stress and regulating energy metabolism.
4. Preclinical Meta-analysis
A systematic review published in *Frontiers in Nutrition* in April 2026 (including 14 mouse NAFLD model studies) quantitatively confirmed that dihydromyricetin significantly reduced liver triglyceride, total cholesterol, transaminase, and inflammatory cytokine levels, while increasing antioxidant enzyme activity and the pAMPK/AMPK ratio. Researchers called for more standardized preclinical designs and high-quality human studies.
Safety Assessment
1. Authoritative Database Evaluation
According to the U.S. LiverTox database, dihydromyricetin preparations have not been found to be associated with serum enzyme elevations or clinically apparent liver injury. This is noteworthy because many herbal supplements carry varying degrees of hepatotoxicity risk.
2. Human Trial Data
In the 2025–2026 MASLD human trial:
- The incidence of adverse events was similar between the DHM group and the placebo group (gastrointestinal discomfort 5.0% vs. 3.3%; headache 3.3% vs. 5.0%)
- No serious adverse events were reported
- All adverse events were mild to moderate and did not lead to study drug discontinuation
3. Traditional Use History
Dihydromyricetin is the main active component of vine tea (Ampelopsis grossedentata), which has been consumed as a daily beverage in some regions of China for hundreds of years, traditionally used for hangover relief and liver protection. This provides additional support for its safety profile.
4. Risk Considerations
| Risk Category | Description |
|---|---|
| Regulatory Status | Sold as a dietary supplement, not an FDA-approved drug; product quality varies widely |
| Special Populations | Safety data are lacking for pregnant/breastfeeding women and patients with severe liver disease |
| Drug Interactions | Interactions with CYP3A4-metabolized drugs have not been systematically studied |
| Bioavailability | Low oral bioavailability (~4%) affects predictability of efficacy |
| Long-term Safety | The longest human study to date is 12 months; data beyond this period are insufficient |
Summary of Current Research Status
1.Evidence Pyramid
|
Evidence Level |
Study Type |
Quantity/Status |
Conclusion |
|---|---|---|---|
|
Highest |
Human RCT |
1 study (n=55) |
Improved liver enzymes and metabolic parameters in MASLD |
|
High |
Preclinical Meta-analysis |
1 study (14 studies included) |
Quantitatively confirmed multi-domain efficacy |
|
Moderate |
Phase I Human Trial |
1 ongoing |
Safety and PK data pending (late 2025) |
|
Foundational |
Animal Studies |
Dozens |
Consistently show protective effects |
2.Main Strengths and Limitations
Strengths:
- Preclinical evidence is highly consistent and validated by meta-analysis
- A high-quality human RCT has shown initial positive results (35% vs. 5%)
- Good safety profile; no hepatotoxicity reports in LiverTox
- In-depth mechanistic studies (AMPK, NLRP3, TLR4 pathways, etc.)
Limitations:
- Small sample size in human studies (only 55 cases); independent validation needed
- Dosage not standardized; low bioavailability (~4%) is a major obstacle
- Lack of human data for alcoholic liver disease, liver fibrosis, and other conditions
- Lack of long-term safety data (>2 years)
Dihydromyricetin Bulk Powder protects the liver through multiple mechanisms, including antioxidant, anti-inflammatory, and lipid metabolism regulation. Key milestones include positive RCT results in the MASLD field (liver enzyme normalization rate 35% vs 5%) and the ongoing Phase I trial in alcoholic liver disease. Overall, the evidence is positive, but limited human data and low bioavailability remain issues to be addressed. For interested users, it is recommended to use this as an adjunct therapy under the guidance of a physician and it should not replace a healthy lifestyle or standard treatment.
Quality guaranteed, stock ready, place your order now!
My email：sales4@lymallpanda.com
WhatsApp：+86 15353955739
